Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

SPRY - ARS Pharmaceuticals, Inc. Последние... | Finranks

Home

/

SPRY

A

ARS Pharmaceuticals, Inc. (SPRY)

NGM – Цена в реальном времени. Валюта: USD

8.54

+0.52 (6.48%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

8.80

+0.26 (3.04%)

После закрытия: Jun 26, 2026, 7:44 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

ARS Pharmaceuticals: Still A Buy As Neffy Access Improves

ARS Pharmaceuticals: Still A Buy As Neffy Access Improves

ARS Pharmaceuticals is now focused on scaling Neffy. This is their needle-free epinephrine spray for severe allergic reactions, and it's also core to my bull case on SPRY. Recently, we've seen SPRY double down on CVS Caremark, Medicaid, retail affordability, and a larger sales force to improve Neffy's access by 2H2026. Neffy is already generating commercial revenue, and the next test for my bull case is whether repeat sales grow as access improves.

ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript

ARS Pharmaceuticals Q1 Earnings Call Highlights

ARS Pharmaceuticals Q1 Earnings Call Highlights

ARS Pharmaceuticals NASDAQ: SPRY reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy, its needle-free epinephrine treatment for allergic reactions including anaphylaxis.

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.35 per share a year ago.

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Q1 2026 total revenue of $22.7 million including neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer.

Видео

No Data

There is no data to display

Пресс-релизы

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Q1 2026 total revenue of $22.7 million including neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

13.05.2026

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe allergic reactions that can lead to anaphylaxis, today announced the appointment of Donn Casale as President, effective June 1, 2026. Richard Lowenthal will continue to lead ARS Pharma as Chief Executive Officer.

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

Children were previously required to weigh ≥33 lbs. and